



TOWARDS RHINOLOGY BEST PRACTICE (TREATMENT OF ABRS)

□ When Should Empiric Antimicrobial Therapy Be Initiated in Patients With Signs and Symptoms Suggestive of acute bacterial rhinosinusitis ABRS? ¹⁻⁹

It is recommended that empiric antimicrobial therapy be initiated as soon as the clinical diagnosis of ABRS is established as listed in previous best clinical practice

□ Should Amoxicillin Versus Amoxicillin-Clavulanate Be Used for Initial Empiric Antimicrobial Therapy of (ABRS) in Children and Adults? ¹⁻⁹

- Amoxicillin-clavulanate rather than amoxicillin alone is recommended as empiric antimicrobial therapy for ABRS in children for 10-14 days and for 5-7 days in adults.

- "High-dose" (2 g orally twice daily or 90 mg/kg/day orally twice daily) amoxicillin-clavulanate is recommended for :

1. children and adults with ABRS from geographic regions with high endemic rates (10%) of invasive penicillin-nonsusceptible (PNS) *S. pneumoniae*,
2. severe infection (e.g, evidence of systemic toxicity with fever of 39C or higher, and threat of suppurative complications),
3. Attendance at daycare and ages less than 2 or more than 65 years,
4. Recent hospitalization, antibiotic use within the past month, or immunocompromised

Prof. Dr. Ahmed Ragab MD, PhD (Brussels)

Prof. ORL H&N Surgery

Menoufia University, Egypt

Email: ahmedragab2000@hotmail.com





TOWARDS RHINOLOGY BEST PRACTICE

□ Which is the most appropriate Second-line antimicrobial therapy for ABRS in Children or Adults? ¹⁻⁹

- Either doxycycline (not suitable for children) or a respiratory fluoroquinolone (levofloxacin or moxifloxacin) is recommended as an alternative agent for empiric antimicrobial therapy in adults who are allergic to penicillin
- Combination therapy with clindamycin plus a third-generation oral cephalosporin (cefixime or cefpodoxime) is recommended in children with a history of non-type I hypersensitivity to penicillin
- Macrolides (clarithromycin and azithromycin) are not recommended for empiric therapy due to high rates of resistance among *S. pneumoniae* (30%)
- Trimethoprim-sulfamethoxazole (TMP/SMX) is not recommended for empiric therapy because of high rates of resistance among both *S. pneumoniae* and *Haemophilus influenzae* (30%–40%) .
- Second-and third-generation oral cephalosporins are no longer recommended for empiric monotherapy of ABRS due to variable rates of resistance among *S. pneumoniae*.

Prof. Dr. Ahmed Ragab MD, PhD (Brussels)

Prof. ORL H&N Surgery

Menoufia University, Egypt

Email:ahmedragab2000@hotmail.com





TOWARDS RHINOLOGY BEST PRACTICE

Other treatment modalities in ABRS¹⁻⁹:

Is Saline Irrigation of the Nasal Sinuses of Benefit as Adjunctive Therapy in Patients With ABRS?

Intranasal saline irrigation with either physiologic or hypertonic saline is recommended

as an adjunctive treatment in adults with ABRS

Are Intranasal Corticosteroids Recommended as an Adjunct to Antimicrobial Therapy in Patients With ABRS?

Intranasal corticosteroids (INCSs) are recommended as an adjunct to antibiotics in the empiric treatment of ABRS, primarily in patients with a history of allergic rhinitis

Should Topical or Oral Decongestants or Antihistamines Be Used as Adjunctive Therapy in Patients With ABRS?

Neither topical nor oral decongestants and/or antihistamines are recommended as adjunctive treatment in patients with ABRS

Prof. Dr. Ahmed Ragab MD, PhD (Brussels)

Prof. ORL H&N Surgery

Menoufia University, Egypt

Email:ahmedragab2000@hotmail.com





References:

- 1-Lanza DC, Kennedy DW. Adult rhinosinusitis defined. *Otolaryngol Head Neck Surg* 1997;117(3 pt 2):S1-7.
- 2-Chow AW, Menninger MS, Brook I, Brozek JL, Goldstein EJ, Hicks LA, Pankey GA, IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. *Clin Infect Dis*. 2012 Apr;54(8):e72-e112.
- 3-Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. *Rhinology*. 2012 Mar;50(1):1-12.
- 4-Eng L, Zhang L, Hu Z, Ehle EA, Chen Y, Liu L, Chen M. Systematic review of evidence-based guidelines on medication therapy for upper respiratory tract infection in children with AGREE instrument. *PLoS One*. 2014 Feb 20;9(2):e87711.
- 5-Kaper NM, Breukel L, Venekamp RP, Grolman W, van der Heijden GJ. Absence of evidence for enhanced benefit of antibiotic therapy on recurrent acute rhinosinusitis episodes: a systematic review of the evidence base. *Otolaryngol Head Neck Surg*. 2013 Nov;149(5):664-7
- 6-de la Poza Abad M, Mas Dalmau G, Moreno Bakedano M, González González AI, Canellas Criado Y, Hernández Anadón S, et al.; Delayed Antibiotic Prescription (DAP) Working Group. Rationale, design and organization of the delayed antibiotic prescription (DAP) trial: a randomized controlled trial of the efficacy and safety of delayed antibiotic prescribing strategies in the non-complicated acute respiratory tract infections in general practice. *BMC Fam Pract*. 2013 May 19;14:63.
- 7-Cronin MJ, Khan S, Saeed S. The role of antibiotics in the treatment of acute rhinosinusitis in children: a systematic review. *Arch Dis Child*. 2013 Apr;98(4):299-303
- 8-Brook I. Amoxicillin-clavulante as the gold standard empirical therapy of acute bacteria rhinosinusitis. *Expert Rev Anti Infect Ther*. 2012 ;10(12):1367-9.
- 9-Meltzer EO, Hamilos DL. Rhinosinusitis diagnosis and management for the clinician: a synopsis of recent consensus guidelines. *Mayo Clin Proc*. 2011 May;86(5):427-43.